A role for TARC/CCL17, a CC chemokine, in New Zealand mice

Authors:

Abstract
Sir, Systemic lupus erythematosus (SLE) is an autoimmune disease in which peripheral helper T2 (Th2) cells have traditionally been considered to predominate. However, contradicting results regarding helper T1 (Th1) predominance in SLE have recently been reported, so the issue of Th1 vs Th2 predominance in SLE patients remains unresolved. To clarify this matter, we have recently published data demonstrating that the plasma levels of thymus- and activation-regulated chemokine (TARC)/CCL17 were highest in untreated SLE patients, and were higher in immunosuppressive-treated SLE patients than in rheumatoid arthritis (RA) patients and healthy donors [1]. TARC/CCL17, a Th2-type CC chemokine, is one of the high-affinity ligands for CCR4, a chemokine receptor that is predominantly expressed on Th2 cells [2]. TARC/CCL17 is reported to be high in plasma from patients with allergic diseases, such as bronchial asthma and atopic dermatitis [3, 4]. These data indicate that Th2 is predominant in the primary pathogenesis of SLE.
Keywords